Q4 2024 · 13F-HR
Vivo Capital, LLCholdings as filed
Filed 2025-02-13 · accession 0001213900-25-013306
$892.6M
Reported value
40
Positions
2024-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 834203309 | SLNO | Soleno Therapeutics Inc | $282.8M | 31.7% | 6,291,851 | Common | SOLE |
| 925050106 | VRNA | Verona Pharma PLC | $106.1M | 11.9% | 2,283,975 | Common | SOLE |
| 374163103 | GERN | Geron Corp | $96.4M | 10.8% | 27,225,292 | Common | SOLE |
| 880881107 | 430 | Terns Pharmaceuticals Inc | $38.2M | 4.28% | 6,895,746 | Common | SOLE |
| G29687103 | AVDL | Avadel Pharmaceuticals PLC | $28.2M | 3.16% | 2,684,109 | Common | SOLE |
| 26818M108 | DYN | Dyne Therapeutics Inc | $26.3M | 2.94% | 1,114,960 | Common | SOLE |
| 00461U105 | ACRS | Aclaris Therapeutics, Inc. | $22.0M | 2.47% | 8,888,888 | Common | SOLE |
| 24661P807 | DCTH | Delcath Systems, Inc. | $20.6M | 2.30% | 1,708,579 | Common | SOLE |
| 92790C104 | VRDN | Viridian Therapeutics Inc | $18.8M | 2.11% | 982,576 | Common | SOLE |
| 171757206 | CDTX | Cidara Therapeutics, Inc. | $18.0M | 2.02% | 670,600 | Common | SOLE |
| 29479A108 | ERAS | Erasca Inc | $17.0M | 1.90% | 6,756,756 | Common | SOLE |
| 89532M101 | TRVI | Trevi Therapeutics Inc | $14.4M | 1.61% | 3,487,903 | Common | SOLE |
| 04635X102 | CATBUSD | Astria Therapeutics Inc | $13.9M | 1.56% | 1,552,685 | Common | SOLE |
| 76200L309 | RZLT | Rezolute Inc | $13.7M | 1.54% | 2,797,704 | Common | SOLE |
| 81749D107 | SERA | Sera Prognostics Inc | $13.4M | 1.51% | 1,650,440 | Common | SOLE |
| 89157D105 | TRML | Tourmaline Bio Inc. | $12.0M | 1.34% | 591,882 | Common | SOLE |
| 221015100 | CRVS | Corvus Pharmaceuticals Holdings | $12.0M | 1.34% | 2,234,566 | Common | SOLE |
| 45783C200 | TIL | Instil Bio Inc | $11.2M | 1.25% | 585,485 | Common | SOLE |
| 68622P109 | ORIC | Oric Pharmaceuticals Inc | $10.3M | 1.16% | 1,277,818 | Common | SOLE |
| 00289Y206 | ABEO | Abeona Therapeutics, Inc. | $10.3M | 1.15% | 1,842,751 | Common | SOLE |
| 98937L105 | ZBIO | Zenas Biopharma Inc | $9.7M | 1.09% | 1,183,260 | Common | SOLE |
| 10919W405 | DRUG | Bright Minds Biosciences Inc | $9.1M | 1.02% | 251,572 | Common | SOLE |
| 68062P106 | OLMA | Olema Pharmaceuticals Inc | $8.8M | 0.98% | 1,505,862 | Common | SOLE |
| 19240Q201 | COGT | Cogent Biosciences Inc | $8.8M | 0.98% | 1,122,471 | Common | SOLE |
| 15102K100 | CELC | Celcuity Inc | $8.0M | 0.90% | 610,500 | Common | SOLE |
| 92337C203 | VSTM | Verastem Inc | $8.0M | 0.89% | 1,538,461 | Common | SOLE |
| 90466Y103 | — | Unicycive Therapeutics | $7.9M | 0.89% | 9,970,152 | Common | SOLE |
| 75915K309 | RGLS | Regulus Therapeutics Inc | $7.9M | 0.89% | 5,000,000 | Common | SOLE |
| 82686Q101 | SLN | Silence Therapeutics PLC | $7.6M | 0.85% | 1,105,454 | Common | SOLE |
| 20451W101 | CMPS | Compass Pathway PLC | $6.1M | 0.68% | 1,608,000 | Common | SOLE |
| 449778109 | IOBTQ | IO Biotech Inc | $5.7M | 0.64% | 6,173,439 | Common | SOLE |
| 01626L204 | ALGS | Aligos Therapeutics Inc | $5.7M | 0.63% | 141,879 | Common | SOLE |
| 20454B104 | CMPX | Compass Therapeutics Inc | $5.2M | 0.58% | 3,556,023 | Common | SOLE |
| 01671P100 | ALLKGUSD | Allakos Inc | $3.6M | 0.40% | 2,956,110 | Common | SOLE |
| 21833P301 | CRBP | Corbus Pharmaceuticals Holdings | $2.0M | 0.22% | 166,794 | Common | SOLE |
| 097702104 | BOLT1EUR | Bolt Therapeutics Inc | $1.9M | 0.21% | 3,521,291 | Common | SOLE |
| 88032L605 | TENX | Tenax Therapeutics Inc | $1.3M | 0.14% | 208,333 | Common | SOLE |
| 23306J309 | DBVT | DBV Technologies SA | $98,942 | 0.01% | 32,020 | Common | SOLE |
| 746964105 | QTTB | Q32 Bio Inc. | $70,723 | 0.01% | 20,559 | Common | SOLE |
| 74019P207 | DTIL | Precision Biosciences Inc | $17,812 | 0.00% | 4,675 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.